SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

March 31, 2011 08:30 ET

Radient Pharmaceuticals Announces Preliminary Results From Its Onko-Sure® Clinical Study

TUSTIN, CA--(Marketwire - March 31, 2011) - Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based company specializing in the research, development, and international commercialization of In Vitro Diagnostic cancer tests, announced today preliminary results from its clinical study conducted in collaboration with a well-recognized, large third-party not-for-profit group practice and its affiliates for the validation of RPC's US FDA‐cleared Onko‐Sure® in vitro diagnostic (IVD) cancer test.

The purpose of the study was to determine the effectiveness of Onko-Sure® (DR-70) as a useful tool in the detection of colorectal cancer in all stages of colorectal cancer (CRC), especially early stages where effective diagnosis leads to better patient prognosis. In addition, this study focused on the effectiveness of Onko-Sure®, Carcinoembryonic Antigen (CEA) and the combination of these two tumor markers for additional clinical value. Based on preliminary results, RPC's Onko-Sure® IVD cancer test shows a statistical advantage over CEA in detecting CRC in the early stages of colorectal cancer. Furthermore, when Onko-Sure® was combined with CEA, the sensitivity of the combined test was substantially improved as opposed to using CEA alone. 

RPC plans to disseminate these results in a peer-reviewed journal, either independently or with other third party healthcare organizations. Additionally, RPC plans to present these results to physicians at international oncology conferences and scientific meetings.

RPC's Executive Chairman and CEO Douglas MacLellan commented, "We are pleased by the preliminary findings of the study and anxiously await the final data set analysis. We acknowledge the diligence and hard work that supporting teams have put into the study. Furthermore, we sincerely appreciate the loyalty of our committed staff and shareholders."

The Company also filed an extension today with the SEC to file its annual report on Form 10-K for the year ending December 31, 2010 on or before April 15, 2011, which is the permissible extension date. 

RPC's Onko-Sure® IVD Cancer Test
RPC's Onko‐Sure® IVD cancer test is a simple, non‐invasive and regulatory-approved in vitro diagnostic (IVD) test used for the detection and monitoring of the treatment and/or recurrence of various types of cancer. The test enables physicians and healthcare professionals to effectively detect and/or monitor certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure® is cleared by the US FDA for detection during colorectal cancer treatment and/or for recurrence monitoring in colorectal cancer patients and by Health Canada for the detection, treatment and/or recurrence monitoring of lung cancer detection and treatment monitoring. For more information visit www.onko-sure.com

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits. The company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or send e-mail to info@radient-pharma.com. For Investor Relations contact Kristine Szarkowitz at IR@RadientPharma.com or 1.206.310.5323.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • RPC Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    (Tel : ) 206.310.5323